Lilly Eli & Co (NYSE:LLY) Big Money Quarterly Sentiment at 1.1

May 17, 2018 - By Benjamin Allen

Eli Lilly and Company (NYSE:LLY) Corporate Logo

Lilly Eli & Co’s Sentiment

In Q4 2017 Lilly Eli & Co (NYSE:LLY) big money sentiment increased to 1.1, SEC.gov filings reveal. So its up 0.21, from 2017Q3’s 0.89. 463 institutional investors started new or increased equity positions, while 422 decreased and sold their stakes in Lilly Eli & Co so the sentiment is more positive. These funds own 827.08 million shares, that’s down from 827.83 million shares in 2017Q3. Funds holding Lilly Eli & Co in top 10 changed to 15 from 19 for a decrease of 4. 42 Investors Sold All; 380 Reduced Holdings; 346 increased holdings while 117 institutional investors bought holdings.

Most Lilly Eli & Co Shareholders

Lilly Endowment Inc owns 123.08 million shares in Lilly Eli & Co as of Q4 2017. As of Q4 2017, 385,549 shares of Lilly Eli & Co are owned by Private Capital Advisors Inc.. Weatherly Asset Management L. P. reported 327,825 shares. The Sweden-based fund Healthinvest Partners Ab have invested about 5.7% of the investment manager’s stock portfolio in Lilly Eli & Co. The New York-based fund Valueworks Llc looks positive on Lilly Eli & Co, owning 69,752 shares.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide.The firm is worth $82.86 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products.Currently it has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

LLY is reaching $81.18 during the last trading session, after decreased 0.57%.Currently Eli Lilly and Company is downtrending after 10.19% change in last May 17, 2017. LLY has also 3.61 million shares volume. LLY underperformed by 21.74% the S&P 500.

Eli Lilly and Company (NYSE:LLY)’s earnings report is anticipated by WallStreet on July, 24, Zacks reports. The EPS diference is $0.23 or 20.72 % up from last years number. Previous year: $1.11; Analysts forcast: $1.34. The profit will be $1.37 billion for LLY if $1.34 EPS becomes true. After $1.34 EPS report previous quarter, Wall Street now sees 0.00 % EPS growth of Eli Lilly and Company.

Clearbridge Invests owns 7,848 shs. Pitcairn holds 0.04% of its capital in Eli Lilly and Company (NYSE:LLY) for 4,765 shs. Td Asset Mgmt Inc reported 0.14% of its capital in Eli Lilly and Company (NYSE:LLY). Bremer Trust Natl Association holds 27,943 shs. Shine Invest Advisory Service owns 1,625 shs. Tru Of Virginia Va invested in 0.03% or 2,610 shs. 1,377 are held by Spectrum Mngmt Grp Incorporated. Tcw Group Inc Inc invested 0.02% in Eli Lilly and Company (NYSE:LLY). Connors Investor Inc holds 0.76% of its capital in Eli Lilly and Company (NYSE:LLY) for 62,392 shs. Martingale Asset Limited Partnership holds 0.63% or 559,684 shs. Dodge And Cox accumulated 20.18 million shs. Moreover, Barnett has 0.01% invested in Eli Lilly and Company (NYSE:LLY). 1,225 were reported by Gradient Invests Ltd Liability Com. California State Teachers Retirement Systems has 1.63M shs for 0.28% of their capital. Greylin Mangement Inc owns 27,015 shs.

Eli Lilly and Company registered $48.49 million net activity with 0 insider buys and 11 insider sales since December 11, 2017. LILLY ENDOWMENT INC sold $14.55M worth of Eli Lilly and Company (NYSE:LLY) on Wednesday, April 25. On Friday, March 16 Shares for $237,600 were sold by Smiley Joshua L. The insider Mahony Susan sold $1.81M. Shares for $65,790 were sold by Zakrowski Donald A on Thursday, March 1.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

In total 10 analysts cover Eli Lilly (NYSE:LLY). “Buy” rating has 4, “Sell” are 1, while 5 are “Hold”. (NYSE:LLY) has 40% bullish analysts. With $105.0 highest and $74 lowest price target, Eli Lilly has $90.50 average price target or 11.48% above the current ($81.18) price. 17 are the (NYSE:LLY)’s ratings reports on 17 May 2018 according to StockzIntelligence Inc. On Wednesday, December 13 the rating was maintained by Credit Suisse with “Hold”. On Tuesday, January 16 Goldman Sachs downgraded the shares of LLY in report to “Hold” rating. On Wednesday, April 25 the stock of Eli Lilly and Company (NYSE:LLY) earned “Market Perform” rating by BMO Capital Markets. On Monday, February 26 Jefferies maintained Eli Lilly and Company (NYSE:LLY) with “Buy” rating. On Thursday, February 1 the stock has “Neutral” rating by Bank of America. On Thursday, February 1 the rating was maintained by Leerink Swann with “Hold”. On Friday, April 13 Jefferies maintained Eli Lilly and Company (NYSE:LLY) rating. Jefferies has “Buy” rating and $9000 target. On Tuesday, January 16 Jefferies maintained the shares of LLY in report with “Buy” rating. The stock rating was maintained by Leerink Swann with “Hold” on Wednesday, December 13. In Tuesday, November 21 report Morgan Stanley maintained it with “Equal-Weight” rating and $90 target.

For more Eli Lilly and Company (NYSE:LLY) news published recently go to: Streetinsider.com, Bizjournals.com, 247Wallst.com, Benzinga.com or Streetinsider.com. The titles are as follows: “Lilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster Headache” published on May 15, 2018, “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs” on May 10, 2018, “Will the FDA Shoot Down Eli Lilly and Incyte Again?” with a publish date: April 20, 2018, “Upcoming Earnings: CAT, LLY And BA Report This Week” and the last “Eli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer Care” with publication date: May 16, 2018.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: